These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 21837367)

  • 1. Homozygosity for the MTX1 c.184T>A (p.S63T) alteration modifies the age of onset in GBA-associated Parkinson's disease.
    Gan-Or Z; Bar-Shira A; Gurevich T; Giladi N; Orr-Urtreger A
    Neurogenetics; 2011 Nov; 12(4):325-32. PubMed ID: 21837367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revisiting the non-Gaucher-GBA-E326K carrier state: Is it sufficient to increase Parkinson's disease risk?
    Goldstein O; Gana-Weisz M; Cohen-Avinoam D; Shiner T; Thaler A; Cedarbaum JM; John S; Lalioti M; Gurevich T; Bar-Shira A; Mirelman A; Giladi N; Orr-Urtreger A
    Mol Genet Metab; 2019 Dec; 128(4):470-475. PubMed ID: 31662221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age at Onset of Parkinson's Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations.
    Yahalom G; Rigbi A; Israeli-Korn S; Krohn L; Rudakou U; Ruskey JA; Benshimol L; Tsafnat T; Gan-Or Z; Hassin-Baer S; Greenbaum L
    J Parkinsons Dis; 2020; 10(3):1123-1132. PubMed ID: 32310186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
    Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
    Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.
    Yahalom G; Greenbaum L; Israeli-Korn S; Fay-Karmon T; Livneh V; Ruskey JA; Roncière L; Alam A; Gan-Or Z; Hassin-Baer S
    Parkinsonism Relat Disord; 2019 May; 62():179-184. PubMed ID: 30573413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LRRK2, GBA and SMPD1 Founder Mutations and Parkinson's Disease in Ashkenazi Jews.
    Dagan E; Schlesinger I; Kurolap A; Ayoub M; Nassar M; Peretz-Aharon J; Gershoni-Baruch R
    Dement Geriatr Cogn Disord; 2016; 42(1-2):1-6. PubMed ID: 27449028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset.
    Gan-Or Z; Giladi N; Rozovski U; Shifrin C; Rosner S; Gurevich T; Bar-Shira A; Orr-Urtreger A
    Neurology; 2008 Jun; 70(24):2277-83. PubMed ID: 18434642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of glucocerebrosidase mutation in a large cohort of sporadic Parkinson's disease in Taiwan.
    Huang CL; Wu-Chou YH; Lai SC; Chang HC; Yeh TH; Weng YH; Chen RS; Huang YZ; Lu CS
    Eur J Neurol; 2011 Oct; 18(10):1227-32. PubMed ID: 21338444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews.
    Aharon-Peretz J; Rosenbaum H; Gershoni-Baruch R
    N Engl J Med; 2004 Nov; 351(19):1972-7. PubMed ID: 15525722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes.
    Alcalay RN; Dinur T; Quinn T; Sakanaka K; Levy O; Waters C; Fahn S; Dorovski T; Chung WK; Pauciulo M; Nichols W; Rana HQ; Balwani M; Bier L; Elstein D; Zimran A
    JAMA Neurol; 2014 Jun; 71(6):752-7. PubMed ID: 24756352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease.
    Clark LN; Ross BM; Wang Y; Mejia-Santana H; Harris J; Louis ED; Cote LJ; Andrews H; Fahn S; Waters C; Ford B; Frucht S; Ottman R; Marder K
    Neurology; 2007 Sep; 69(12):1270-7. PubMed ID: 17875915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews.
    Dagan E; Schlesinger I; Ayoub M; Mory A; Nassar M; Kurolap A; Peretz-Aharon J; Gershoni-Baruch R
    Parkinsonism Relat Disord; 2015 Sep; 21(9):1067-71. PubMed ID: 26169695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.
    Sidransky E; Nalls MA; Aasly JO; Aharon-Peretz J; Annesi G; Barbosa ER; Bar-Shira A; Berg D; Bras J; Brice A; Chen CM; Clark LN; Condroyer C; De Marco EV; Dürr A; Eblan MJ; Fahn S; Farrer MJ; Fung HC; Gan-Or Z; Gasser T; Gershoni-Baruch R; Giladi N; Griffith A; Gurevich T; Januario C; Kropp P; Lang AE; Lee-Chen GJ; Lesage S; Marder K; Mata IF; Mirelman A; Mitsui J; Mizuta I; Nicoletti G; Oliveira C; Ottman R; Orr-Urtreger A; Pereira LV; Quattrone A; Rogaeva E; Rolfs A; Rosenbaum H; Rozenberg R; Samii A; Samaddar T; Schulte C; Sharma M; Singleton A; Spitz M; Tan EK; Tayebi N; Toda T; Troiano AR; Tsuji S; Wittstock M; Wolfsberg TG; Wu YR; Zabetian CP; Zhao Y; Ziegler SG
    N Engl J Med; 2009 Oct; 361(17):1651-61. PubMed ID: 19846850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Frequency of GBA Gene Mutations in Dementia With Lewy Bodies Among Ashkenazi Jews.
    Shiner T; Mirelman A; Gana Weisz M; Bar-Shira A; Ash E; Cialic R; Nevler N; Gurevich T; Bregman N; Orr-Urtreger A; Giladi N
    JAMA Neurol; 2016 Dec; 73(12):1448-1453. PubMed ID: 27723861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in the glucocerebrosidase gene are common in patients with Parkinson's disease from Eastern Canada.
    Han F; Grimes DA; Li F; Wang T; Yu Z; Song N; Wu S; Racacho L; Bulman DE
    Int J Neurosci; 2016; 126(5):415-21. PubMed ID: 26000814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variants in PSMB9 and FGR differentially affect Parkinson's disease risk in GBA and LRRK2 mutation carriers.
    Shani S; Goldstein O; Gana-Weisz M; Bar-Shira A; Thaler A; Gurevich T; Mirelman A; Giladi N; Alcalay RN; Orr-Urtreger A
    Parkinsonism Relat Disord; 2023 Jun; 111():105398. PubMed ID: 37116292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trio approach reveals higher risk of PD in carriers of severe vs. mild GBA mutations.
    Arkadir D; Dinur T; Mullin S; Mehta A; Baris HN; Alcalay RN; Zimran A
    Blood Cells Mol Dis; 2018 Feb; 68():115-116. PubMed ID: 27864021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Features of
    Malek N; Weil RS; Bresner C; Lawton MA; Grosset KA; Tan M; Bajaj N; Barker RA; Burn DJ; Foltynie T; Hardy J; Wood NW; Ben-Shlomo Y; Williams NW; Grosset DG; Morris HR;
    J Neurol Neurosurg Psychiatry; 2018 Jul; 89(7):702-709. PubMed ID: 29378790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of severe vs mild GBA mutations on Parkinson disease.
    Gan-Or Z; Amshalom I; Kilarski LL; Bar-Shira A; Gana-Weisz M; Mirelman A; Marder K; Bressman S; Giladi N; Orr-Urtreger A
    Neurology; 2015 Mar; 84(9):880-7. PubMed ID: 25653295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.